bioMérieux, a world leader in the field of in vitro diagnostics, today announced an increase of its shareholding in Suzhou Hybiome Biomedical Engineering Co. Ltd. This announcement follows the earlier announcement of the acquisition of a majority stake in this company in November 2018.
Founded in 2009 and located in Suzhou (China), Hybiome is specialized in automated immunoassay tests. The company develops, manufactures and markets a complete range of diagnostic solutions (reagents, instruments and software) cleared by the National Medical Products Administration (NMPA). In Q1 2019, Hybiome successfully continued to develop its commercial reach into the rapidly growing Grade 2 hospital market.
An additional 13% stake has been acquired for about 20 million euros. Following this transaction, bioMérieux now holds 67% of the shares of Hybiome.
BIOMÉRIEUX IN CHINA
The Mérieux family has developed close ties with China spanning three generations. Today China holds an important position in the strategy of bioMérieux:
- 2nd largest bioMérieux subsidiary in terms of revenue
- 6 offices: Shanghai, Beijing, Chengdu, Guangzhou, Suzhou, Hong Kong and Taipei
In addition, the Company is committed to promoting educational programs for healthcare professionals, with a focus on the medical and economic value of diagnostics and initiatives to raise awareness about major public health challenges, such as antimicrobial resistance.